The Latest

  • Employees working in the labs of Rapport Therapeutics, which recently began late-stage testing of a potentially first-of-its-kind seizure medication.
    Image attribution tooltip
    Permission granted by Rapport Therapeutics
    Image attribution tooltip
    Q&A

    Rapport ‘fully prepared’ to launch seizure drug solo, CEO says

    In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.

  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis RNA drug acquired in $12B Avidity deal notches a trial win

    The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Kardigan set terms Thursday for its IPO, which could bring in more than $373 million for the cardiac drugmaker as it seeks to be the 13th biotechnology company to go public in 2026.

    Updated June 11, 2026
  • Weight loss GLP-1
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit pulls $500M share sale a day after announcing it

    The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    GSK’s $10.6 billion acquisition of Nuvalent is its third company buyout since late January and the biopharmaceutical sector’s second-largest deal this year.

    Updated June 9, 2026
  • An infant's left ear is in the foreground of this image, which is otherwise blurred.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.

  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    Sanofi stops immune drug trial in latest research setback

    The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ethyreal starts up with $101M and takes aim at a pair of immune diseases

    The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.

    Updated June 1, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK boosts cancer pipeline with $11B Nuvalent buyout

    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

  • A person stands next to a table where another person sits.
    Image attribution tooltip
    Courtesy of Treeline Biosciences
    Image attribution tooltip
    Emerging biotech

    Stealthy startup Treeline plans a reverse merger

    Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.

    Updated May 28, 2026
  • Johnson & Johnson's new logo is seen on an office lobby wall.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip
    Emerging biotech

    J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B

    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

    Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

  • lung target
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

    While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

  • Illustration of a blood clot blocking red blood cells within an artery or a vein.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    City banks nearly $100M for next-gen RNAi drugs

    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

  • Pancreatic cancer cells are stained pink in this micrograph image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tango data add to growing momentum for pancreatic cancer drugs

    A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.

  • An illustration of red blood cells
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Incyte to buy blood disorder drug in possibly $2B deal

    Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche stakes $700M on Nurix’s protein-degrading drug

    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

  • capitol china flag
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    House bill aims to crack down on China biotech deals

    A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.

  • Image of a brain in purple outline with red details.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Study data convince Lundbeck to push new migraine drug forward

    A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.